Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Amita Patnaik, MD, FRCP(C)
South Texas Accelerated Research Therapeutics, LLC
Principal Investigator - David Ross Camidge, MD, PhD
University of Colorado, Denver
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rigshospitalet
Copenhagen, Denmark
- Queen Mary Hospital
Hong Kong, Hong Kong
- Cha Bundang Medical Center, Cha University
Seongnam-si, Gyeonggi-do, South Korea
- Asan Medical Center
Seoul, South Korea
- Gangnam Severance Hospital, Yonsei University Health System
Seoul, South Korea
- Korea University Guro Hospital
Seoul, South Korea
- Samsung Medical Center
Seoul, South Korea
- Severance Hospital, Yonsei University Health System
Seoul, South Korea
- Hospital Clinic de Barcelona
Barcelona, Barcelona/Cataluna, Spain
- Hospital Universitario Quiron Dexeus
Barcelona, Barcelona/Cataluna, Spain
- Hospital Universitario Vall D'Hebron
Barcelona, Barcelona/Cataluna, Spain
- Centro Oncologico Md Anderson
Madrid, Spain
- China Medical University Hospital
Taichung, Taiwan
- Taichung Veterans General Hospital
Taichung, Taiwan
- National Cheng Kung University Hospital
Tainan, Taiwan
- Taipei Medical University Hospital
Taipei, Taiwan
- Tri-Service General Hospital
Taipei, Taiwan
- University of Colorado Cancer Center
Aurora, Colorado, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Dana Farber Cancer Institute/d -1251
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- the University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
- South Texas Accelerated Research Therapeutics, Llc
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2016
- Primary completion
- 31 Dec 2020
- Completion
- 31 Dec 2020
- Last update posted
- 22 Jun 2022
- Registered enrollment
- 57
- Registry id
- NCT02648724
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.